drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific monoclonal antibody; T-cell–redirecting immunotherapy)
drug_description
A human bispecific IgG antibody (anti-BCMA × anti-CD3), also known as REGN5458 and Lynozyfic, administered intravenously. It redirects T cells to kill BCMA-expressing myeloma cells by simultaneously binding BCMA on plasma cells and CD3 on T cells, forming an immune synapse and inducing cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Linvoseltamab is a human bispecific IgG antibody (anti-BCMA × anti-CD3) that redirects T cells to kill BCMA-expressing myeloma cells by simultaneously binding BCMA on plasma cells and CD3 on T cells, forming an immune synapse that activates T cells and triggers perforin/granzyme-mediated cytotoxicity and cytokine release.
drug_name
Linvoseltamab
nct_id_drug_ref
NCT05828511